{"disease":{"id":"neoadjuvant-treatment","name":"neoadjuvant treatment"},"drugs":{"marketed":[{"drug_id":"chembl-chembl3301589","indication_name":"Neoadjuvant and Adjuvant Treatment of MIBC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01864746","title":"A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":true},{"nct_id":"NCT03177382","title":"Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":458,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04280822","title":"Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06758830","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","has_results":false},{"nct_id":"NCT06372886","title":"Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07198165","title":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06668402","title":"Study of Daily Step Count and Treatment Response in Rectal Cancer (STEP-R)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Gazi University","has_results":false},{"nct_id":"NCT05382052","title":"Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT06472635","title":"a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT02489006","title":"A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":71,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04858516","title":"Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT07286253","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","has_results":false},{"nct_id":"NCT04906044","title":"Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT06959511","title":"Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05998122","title":"Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT05524012","title":"Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Jena University Hospital","has_results":false},{"nct_id":"NCT05356351","title":"An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04622566","title":"Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":26,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05343325","title":"The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05111860","title":"Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shanghai Minimally Invasive Surgery Center","has_results":false},{"nct_id":"NCT03479814","title":"Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04620473","title":"Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shanghai Minimally Invasive Surgery Center","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}